During Monday’s current trade, Intrexon Corp (NYSE:XON)’s shares decline -0.92% to $49.92.
Intrexon Corporation (XON) declared that it has reached a partnership with an investment fund sponsored by Harvest Capital Strategies, LLC. The fund is believed to be the world’s first that is dedicated to the inventions and discoveries of a single company.
Intrexon has agreed to provide the fund a noteworthy number of investment proposals from across five sectors – Health, Energy, Food, Environment and Consumer – that are suitable for pursuit by a startup, counting several in 2015. With respect to such proposals, Intrexon will provide the fund with exclusive rights of first-look and first negotiation. Intrexon presently sees the potential to form up to ten new companies per year, each of which will have access to Intrexon’s proprietary technology platform through an Exclusive Channel Collaboration. Although the partnership with the fund will be complimentary to programs already underway at Intrexon, nothing in the arrangement will limit the Company’s ability to execute other collaborations and joint ventures.
Intrexon Corporation, a biotechnology company, operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that comprise of key genetic components. Its technologies comprise UltraVector gene design and fabrication platform, and its associated library of modular DNA components; cell systems informatics; RheoSwitch inducible gene switch; AttSite Recombinases; protein engineering; mAbLogix; and laser-enabled analysis and processing. Intrexon Corporation has partnership agreements with ZIOPHARM Oncology, Inc.; Synthetic Biologics, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; AquaBounty Technologies, Inc.; S & I Ophthalmic, LLC; Biological & Popular Culture, Inc.; OvaXon, LLC; Intrexon Energy Partners, LLC; and Persea Bio, LLC; and planned partnershipand licensing agreement with Merck Serono S.A. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.
Calithera Biosciences Inc (NASDAQ:CALA)‘s shares gain 1.62% to $8.80, during the current trading session Monday’s, hitting its highest level.
Calithera Biosciences, Inc. (CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced its participation at the JMP Securities Life Sciences Conference 2015. Susan M. Molineaux, Ph.D., Founder, President and Chief Executive, will present on Tuesday, June 23, 2015 at 9:30 a.m. Eastern Time at The St. Regis Hotel in New York, NY. The presentation will be webcast live and available for replay for up to 30 days at www.calithera.com under the tab Investors.
Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate comprises CB-839, an inhibitor of glutaminase, which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma.
In an afternoon trade, Clean Diesel Technologies, Inc. (NASDAQ:CDTI)‘s shares plunge -2.46% to $1.98.
Clean Diesel Technologies, Inc. (CDTI) declared that it is raising about $5.1 million in gross proceeds in an underwritten public offering of 2,500,000 common stock units at a purchase price of $2.05 per unit. Each unit will comprise of one share of the Company’s common stock and 0.2 of a warrant to purchase one share of common stock. The warrants are exercisable six months and one day after the date of issuance at an exercise price of $2.65 per share and will expire, unless exercised, five years from the date they first become exercisable.
The net proceeds from the sale of the shares and the related warrants, after deducting underwriting discounts, commissions and expense reimbursements and other estimated offering expenses payable by CDTi, will be about $4.5 million, which does not comprise any potential proceeds from the cash exercise of any warrants. CDTi intends to use the net proceeds from this offering (counting any resulting from the exercise of the warrants, if any) for general corporate purposes, counting, but not limited to, working capital, general and administrative expenses, capital expenditures, implementation of planned priorities, and as otherwise revealed in the prospectus supplement.
Clean Diesel Technologies, Inc. manufactures and distributes light duty vehicle catalysts and heavy duty diesel emissions control systems and products to automakers, distributors, integrators, and retrofitters in the United States, Canada, Sweden, and the United Kingdom. It operates through two divisions, Catalyst and Heavy Duty Diesel Systems. The Catalyst division develops and produces catalysts to reduce emissions from gasoline, diesel, and natural gas combustion engines.
SunPower Corporation (NASDAQ:SPWR), during its Monday’s current trading session 0.60% gain and closed at $31.85.
A joint venture between two solar PV makers has set its terms for an initial public offering (IPO) that is predictable to price next week. 8point3 Energy Partners is a solar energy yieldco formed by SunPower Corp. ( SPWR) and First Solar Inc. ( FSLR).
The new company’s initial portfolio of assets comprises 262 megawatts of generation from four First Solar-owned plants and 163 megawatts of generation from SunPower-owned plants. The partners have also award rights of first offer to 8point3 on another 1,143 megawatts of generation.
8point3 is organized as a limited partnership and will be treated as a corporation for U.S. federal income tax purposes. Distributions to the holders of the company’s shares will be taxable as ordinary dividend income to the extent of 8point3’s current and accumulated earnings and profits as computed for U.S. federal income tax purposes. The company anticipates to pay an annual distribution of $0.8388 per share initially, and it is targeting its annual distribution growth rate at 12% to 15% per share for the three years following the IPO.
SunPower Corporation designs, manufactures, and delivers solar systems to residential, commercial, and utility-scale power plant customers worldwide. The company offers solar power components, counting panels, balance of system components, and inverters. It also offers rooftop and ground-mounted solar power systems, counting residential systems, commercial roof and ground mounted systems, utility and power plant systems, and utility-scale photovoltaic power plants.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
